GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice-Reference-Cited by-同舟云学术

GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice

Published:2021-03 Issue: Volume:Volume 14 Page:1095-1105
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Nakamura Takashi^ORCID,Tanimoto Hitomi,Okamoto Masayuki,Takeuchi Mitsuaki,Tsubamoto Yoshiharu,Noda Hitoshi

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Reference39 articles.

1. WHO. World Health Organization: obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed February 20, 2021.

2. CDC. Centers for disease control and prevention: healthy weight. the health effects of overweight and obesity. Available from: https://www.cdc.gov/healthyweight/effects/index.html. Accessed February 20, 2021.

3. STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN.1

4. Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology;Peptides;2024-07

2. Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology;Journal of Diabetology;2024-01

3. Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future;Advances in Protein Chemistry and Structural Biology;2024

4. 360-Degree Perspectives on Obesity;Medicina;2023-06-09

5. Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes;Journal of Diabetes Research;2023-04-15